LSNE expands lyophilization capacity at Madison, USA

This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site

LSNE a leading global contract development and manufacturing organization (CDMO), announced that it has doubled its sterile drug product lyophilization capacity at its Madison, Wisconsin parenteral manufacturing facility, with the installation of a new lyophilizer. The Madison capacity increase is one step in a strategic company-wide lyophilization expansion plan adding capacity to all existing facilities.

"In response to our clients' needs, we have expanded our lyophilization capacity. There continues to be an uptick in their demand for lyophilization and we accelerated our plans to add capacity to be ready this month," explains Doug Craig, Site Head at LSNE-Madison.

As a leader in lyophilization services, LSNE is capitalising on its expertise and high-speed fill line at the Wisconsin cGMP sterile drug product manufacturing facility to bring on a new 120 ft commercial lyophilizer. This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site. This added capacity will help address long industry timelines for lyophilization and support our clients ever-increasing capacity demands.